Back

Comparison of embolism and bleeding risk profile in patients with atrial fibrillation and chronic kidney disease

28 August 2022 (10:55 - 11:05)
Organised by:
Congress Presentation Part of: Clinical challenges in atrial fibrillation Stroke Prevention ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Jose Antonio Parada Barcia

Hospital Universitario Alvaro Cunqueiro, Vigo (Spain)

5 More presentations in this session

Presentation thumbnail
Perioperative atrial fibrillation in major emergency abdominal surgery: does it affect postoperative outcome?
Miss A. Tas (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Temporal trends and patterns in atrial fibrillation incidence: a population-based study of 3.4 million individuals
Mr K. Raveendra (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Searching for underlying atrial fibrillation using artificial intelligence-assisted MRI images from ischemic stroke patients
Doctor Z. Zhang (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Impact of metabolic syndrome on the risk of ischemic stroke in non-anticoagulated atrial fibrillation patients having low CHA2DS2-VASc scores
Doctor H. Ahn (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Watchman device migration and embolization: a report from the NCDR LAAO registry
Doctor D. Friedman (Durham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical challenges in atrial fibrillation

The Event

Event poster

ESC Congress 2022

28 August 2022 10:55 CET
You may be interested in
thumbnail
Congress Session
Atrial fibrillation and stroke: role of kidney disease and biomarkers
thumbnail
Congress Presentation
Stroke, mortality, and major bleeding among patients with atrial fibrillation and chronic kidney disease; insights from a contemporary large-scale population study
thumbnail
Congress Presentation
Atrial fibrillation and chronic kidney failure: who and how to anticoagulate

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources